Silver Oak Securities Incorporated Acquires 1,045 Shares of Johnson & Johnson (NYSE:JNJ)

Silver Oak Securities Incorporated raised its stake in Johnson & Johnson (NYSE:JNJ) by 13.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 8,637 shares of the company’s stock after acquiring an additional 1,045 shares during the period. Silver Oak Securities Incorporated’s holdings in Johnson & Johnson were worth $1,414,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Vanguard Group Inc. increased its stake in Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock valued at $8,321,881,000 after acquiring an additional 1,561,036 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. Finally, Wellington Management Group LLP raised its holdings in Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after acquiring an additional 431,205 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.2%

Shares of Johnson & Johnson stock opened at $155.90 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a market cap of $375.11 billion, a PE ratio of 17.34, a PEG ratio of 2.36 and a beta of 0.41. The firm has a 50-day moving average of $153.68 and a 200-day moving average of $154.09. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on JNJ shares. Barclays decreased their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Finally, Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.